Showing results (1171-1180 of 6,669) with videos related to

Sort By:
Pageof 667
Annals of Hematology|April 24, 2023
Autoimmune Hemolytic Anemia in the Pediatric Age Group: The Egyptian ExperienceAmina Abdel-Salam, Sherifa Tarek Bassiouni, Alaa Magdi Goher, et al.
Annals of Hematology|April 24, 2023
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysisKimberley Doucette, Allison O Taylor, Bryan Chan, et al.
Annals of Hematology|August 11, 2020
Association between BCL11A, HSB1L-MYB, and XmnI γG-158 (C/T) gene polymorphism and hemoglobin F level in Egyptian sickle cell disease patientsMona El-Ghamrawy, Marianne E Yassa, Angie M S Tousson, et al.
Annals of Hematology|July 5, 2014
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trialMariam G Aslanyan, Leonie I Kroeze, Saskia M C Langemeijer, et al.
Annals of Hematology|August 1, 2012
NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantationPeter S Haas, Gabriele Ihorst, Susanne Schnitzler, et al.
Annals of Hematology|September 1, 2012
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopeniaLucia Catani, Daria Sollazzo, Sara Trabanelli, et al.
Annals of Hematology|September 6, 2012
Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classificationP Font, J Loscertales, C Benavente, et al.
Annals of Hematology|September 8, 2012
The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myelomaNoemí Puig, María E Sarasquete, Miguel Alcoceba, et al.
Annals of Hematology|September 13, 2012
Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cellsNa Shao, Daoxin Ma, Jianbo Wang, et al.
Annals of Hematology|April 29, 2023
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effectsInge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, et al.
Pageof 667